EverHint – Momentum Swing — Volatile High Beta for Feb 25, 2026 – 4 Signals – Technology Leads (2)

What This Signal Is (Quick)

Volatile High Beta is a momentum swing trading strategy focused on High volatility stocks (60%+) - for risk-tolerant traders.

Signal Type: Breakout (momentum continuation)

What Makes This Signal:

• Stock showing strong momentum near or at highs
• Increased volume confirms institutional interest
• Breaking out or consolidating near resistance
• High volatility stocks (60%+) - for risk-tolerant traders

Ideal For: Risk-tolerant traders comfortable with high volatility and large price swings

Key Criteria:

• Strong RSI momentum (configurable thresholds)

• Volume surge above average

• Price momentum confirmation

• Minimum ADV: $25M+ (varies by variant)

• Earnings buffer: 7 days pre/post earnings

• Variant-specific filters applied

Holding Period: 1-4 weeks
Risk Level: Medium-High

How We Ranked Today

Ranked by composite momentum score (higher = stronger momentum)

📊 Momentum Swing — Volatile High Beta Signals (4 Total)

Ranked by score:

Field Notes

Sector concentration: Technology (2), Industrials (1), Healthcare (1)

Insider selling: PLAB (Photronics, Inc., $-5.9M), VIR (Vir Biotechnology, Inc., $-132K)

Data coverage: 50.0% insider, 0.0% congressional, 100.0% earnings, 100.0% analyst, 50.0% news

Peer Analysis

Understanding how these stocks relate to their industry peers:

STRL (Sterling Infrastructure, Inc.): Leads 9 peers: BLD ($485.32, -5.0%), STN ($90.27, +2.9%), BLDR ($102.63, -6.4%), HII ($435.58, -2.7%), WMS ($170.00, -0.5%) | Peer of: APG ($44.76, -0.5%), AYI ($306.54, +1.1%), BLD ($485.32, -5.0%) and 5 more

PLAB (Photronics, Inc.): Leads 10 peers: HIMX ($7.71, +0.1%), MXL ($18.64, +2.1%), UCTT ($67.32, -6.5%), LASR ($60.60, +5.1%), CNXN ($60.81, +1.1%) | Peer of: CNXN ($60.81, +1.1%), HIMX ($7.71, +0.1%), LASR ($60.60, +5.1%) and 6 more

VICR (Vicor Corporation): Leads 10 peers: PLXS ($204.09, +0.1%), OSIS ($295.26, -0.9%), NOVT ($133.22, -3.1%), ST ($37.86, -1.3%), ITRI ($97.15, -0.7%) | Peer of: BMI ($155.79, -1.6%), DXC ($12.05, +1.1%), ESE ($279.10, -2.3%) and 11 more

VIR (Vir Biotechnology, Inc.): Leads 9 peers: MRVI ($3.26, +4.5%), IOVA ($3.83, +1.3%), REPL ($8.20, -1.9%), PRME ($4.13, +7.8%), DNA ($9.38, +5.9%) | Peer of: CDNA ($18.46, -4.1%), CSTL ($30.83, +3.0%), DAWN ($10.93, -9.1%) and 11 more

Recent Headlines

VICR (Vicor Corporation)

• Vicor Target of Unusually High Options Trading (NASDAQ:VICR) (source)
• Vicor Corporation (VICR) Q4 2025 Earnings Call Transcript (source)

VIR (Vir Biotechnology, Inc.)

• Vir Biotechnology Announces Pricing of Public Offering of Common Stock (source)
• Vir Biotechnology Announces Proposed Public Offering of Common Stock (source)
• Vir Biotechnology: Up On Prostate Data And Astellas Deal - I'm (Long-Term) Bullish (source)
• These Analysts Boost Their Forecasts On Vir Biotechnology (source)
• Stock Market Today: S&P 500 Futures Slip As Dow, Nasdaq 100 Gain Following Trump's Tariff Threat — Whirlpool, Uber, HP In Focus (UPDATED) (source)
• What's Happening With VIR Stock? (source)
• Vir Biotechnology, Inc. (VIR) Q4 2025 Earnings Call Transcript (source)
• Vir Biotechnology, Inc. (VIR) Reports Q4 Loss, Beats Revenue Estimates (source)
• Vir Biotech Catapults 65% On A $1.71 Billion Deal With Astellas (source)
• Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results (source)
• Vir Biotechnology Reports Positive Updated Phase 1 Results for PSMA-targeting, PRO-XTEN® Dual-masked T-Cell Engager VIR-5500 in Patients with Metastatic Prostate Cancer (source)
• Astellas and Vir Biotechnology Announce Global Strategic Collaboration to Advance PSMA-targeting PRO-XTEN® Dual-masked T-Cell Engager VIR-5500 for the Treatment of Prostate Cancer (source)

Market Context

Broad market indices advanced modestly today, with the Nasdaq leading gains at +0.64%, followed by the S&P 500 at +0.45% and the Dow Jones at +0.27%. This upward trend signals positive risk appetite, favoring momentum-driven strategies that capitalize on swing trades in high beta assets. The top sector's outperformance aligns with rotation toward growth-oriented areas, providing tailwinds for volatile momentum plays amid sustained buying pressure.

The VIX declined sharply by 8.52% to 17.92, reflecting reduced fear and calmer intraday conditions. While this moderation tempers extreme swings ideal for high-volatility strategies, the level remains moderately elevated, preserving opportunities for momentum swings in high beta names without excessive whipsaws. Lower volatility supports trend continuation, allowing positions to build in a risk-on environment.

Sector dynamics underscore technology's leadership, amplifying potential for high beta signals in this space. With broad indices grinding higher, risk appetite bolsters conviction in momentum setups, though traders should monitor for any VIX rebound that could compress swings and heighten reversal risks.

Sharing Call-to-Action

📊 A simple like, share, or subscribe helps this channel reach more traders who follow data, not noise.

Independent, data-driven signals.
No hype. No promotions. Just experimental market research from EverHint.

This is not financial advice. Do your own due diligence.
See https://www.everhint.com/disclaimer/ and https://www.everhint.com/faqs/